Patient-specific tumor-associated antigen presented on MHC class II (MHC II-restricted neoantigen)

Patient-specific tumor-associated antigens, commonly known as neoantigens, are unique peptides resulting from somatic mutations in a patient's tumor cells that are absent in normal tissues (Sahin et al., Nature 2017). When these neoantigens are processed and presented on Major Histocompatibility Complex (MHC) class II molecules, they are recognized by the T-cell receptors (TCRs) of CD4+ T cells, which play a pivotal role in orchestrating the adaptive immune response (Alspach et al., Nature 2019). While historical focus was on MHC class I and CD8+ T cells, recent research highlights that MHC class II-restricted neoantigens are often the dominant targets of successful cancer immunotherapies (Kreiter et al., Nature 2015). These antigens are utilized in the development of personalized cancer vaccines, such as mRNA-based platforms, which aim to prime the immune system to recognize the specific mutational landscape of an individual's malignancy (Ott et al., Nature 2017). By activating CD4+ T cells, these therapies promote the recruitment and activation of cytotoxic CD8+ T cells and enhance long-term immunological memory. However, the clinical application of these targets faces challenges including the high complexity of neoantigen prediction, the necessity for patient-specific manufacturing, and potential tumor escape mechanisms like MHC downregulation (Sahin et al., Science 2018).

Other names

NeoantigenTumor-specific antigenTSAMHC II-restricted tumor antigenPersonalized tumor antigenMHC class II-restricted neoepitope

Vaccine-mediated induction of neoantigen presentation on MHC class II to activate CD4+ T-helper cells, which coordinate a multi-effector anti-tumor immune response.